Resources
Conference videos: the 2026 sessions that matter for CMT2C
Two CMT conferences took place this fall, and both have put their recordings online for everyone. Here are the sessions I found most relevant to CMT2C, each with a short note, and the rest grouped by theme so you can find what interests you.
At a glanceThe CMT Research Foundation's Global CMT Research Convention (24 to 26 September 2026) and the Charcot-Marie-Tooth Association's Patient & Research Summit (9 to 11 October 2026) both heard a company update on the drug built for CMT2C, now called STAR-0871 (previously ABS-0871), and both had sessions on how clinical trials work, how the FDA judges CMT treatments, and how patients shape trial design. The recordings are free to watch [320] [323].
24 to 26 September 2026 · Cambridge, Massachusetts
2026 Global CMT Research Convention
The CMT Research Foundation's yearly meeting: two days for researchers, clinicians and industry, then a Patient Experience Day on the Saturday [179]. On 29 October 2026 the foundation put all 48 talks online, each marked as patient-friendly or technical, on a free platform you can browse by topic [320] [321].
9 to 11 October 2026 · Redwood City, California
2026 CMTA Patient & Research Summit
The Charcot-Marie-Tooth Association's in-person weekend: a Saturday on living well with CMT and a Sunday on research, from discovery to delivery [322]. The CMTA posted recordings of 17 sessions on its YouTube channel in the two weeks after the summit [323].
Start here if you have CMT2C
A good place to start: the sessions that touch CMT2C most directly, in that order.
- Built for CMT2C
Clinical trial updates from companies: Dr. David Goldstein (Actio Biosciences, now Setara)
CMTRF convention, Saturday 26 September 2026
The company update on the TRPV4 blocker developed for CMT2C, given four weeks before the company launched as Setara Biosciences (spun out of Actio Biosciences) and renamed the drug STAR-0871 (previously ABS-0871) [318]. It was part of the Clinical Trials Updates Session on Patient Day, where companies said where their programs stand [179]. Dr. Goldstein founded Actio and is Setara's president and executive chair [319]. Why this drug matters to us.
- Built for CMT2C
Clinical trials: the industry perspective
CMTA summit, Sunday 11 October 2026 · 41 minutes
A panel with the companies developing CMT treatments, including Dr. Goldstein for Actio Biosciences (now Setara), on where their programs stand, the challenges they face, how decisions are made about who can take part, and how the CMTA and the patient community are helping [322].
- Our community
The patient voice in clinical trials
CMTA summit, Sunday 11 October 2026 · 33 minutes
Dr. Katherine Forsey, the CMTA's chief research officer, with patients from the NMD Pharma trial, the SORD trial, the ACT-CMT study and the CMT2C patient group, on what taking part in research is really like [322].
- The FDA
FDA and CMT: how the FDA thinks about CMT evaluation
CMTRF convention, Saturday 26 September 2026 · Dr. Teresa Buracchio, US Food and Drug Administration
How regulators evaluate potential CMT therapies [321]. Useful background for anyone following the FDA listening session for our community on 20 October and the road ahead for STAR-0871.
- Natural history
Why visit an Inherited Neuropathy Consortium site
CMTRF convention, Saturday 26 September 2026 · Dr. Vera Fridman, University of Colorado
The INC's natural history study is open to every type of CMT and is where the 2025 TRPV4 registry data came from [52] [3]. This talk explains what a visit involves and why it matters for trials. How to join.
Global CMT Research Convention (CMTRF), 24 to 26 September 2026
Thursday and Friday were designed for scientists, clinicians and investors, Saturday for patients [179]. The platform marks each talk as patient-friendly or technical and lets you browse by subject [320]. Beyond the picks above, these sessions are the ones I would point a CMT2C family to.
Getting ready for trials
- Patient-friendly
What to expect in a clinical trial
Jenneen DeFiore, PPD (part of Thermo Fisher Scientific) · Saturday
Screening, study visits and what a typical trial day looks like, step by step [321].
- Patient-friendly
How I chose to participate in a clinical trial
Paul-Andre Archambalt and Peter DeSilva · Saturday
A firsthand account from people who have been through a CMT trial [321].
- Patient-friendly
Patient perspectives to inform therapeutic development and trial design
Patient forum moderated by Susan Ruediger, CMTRF · Friday
Researchers designing the next CMT trials hear directly from the patients those trials are meant to serve [321].
- Patient-friendly
Many roads to treating Charcot-Marie-Tooth disease
Dr. Meghan Drummond, CMT Research Foundation · Saturday
A survey of the whole pipeline, from small molecules to gene therapy, listed on the program as “The rest of the pipeline” [179].
- Patient-friendly
The pros and cons of genetic testing
Dr. Marina Kennerson, ANZAC Research Institute and University of Sydney · Saturday
Trials recruit by subtype, so a confirmed genetic diagnosis is the first step [53]. Reading a TRPV4 result.
Measuring what matters in CMT2C
The TRPV4 registry authors wrote that standard CMT scales miss the uneven weakness, the vocal fold weakness and the breathing involvement of our disease, and called for outcome measures that capture them [3]. These Friday talks are about exactly that problem, for CMT as a whole.
- Technical
Clinical outcome measures and biomarkers for CMT: are we ready for clinical trials?
Dr. Vera Fridman, University of Colorado · Friday
- Technical
Beyond patient-reported outcomes: defining meaningful clinical endpoints in CMT
Dr. Bopha Chrea, University of Iowa · Friday
- Technical
DANCER: a new, patient-partnered platform for clinical trials in CMT
Dr. Wolfgang Pernice, Columbia University Irving Medical Center · Friday
Movement analysis from smartphone video. A patient-friendly version, “Using AI to build better outcome measurements”, was given on the Saturday [179].
- Technical
Clinical trial endpoints: discussion panel
Moderated by Dr. Brett McCray, University of Michigan · Friday
Dr. McCray is a TRPV4 researcher and the first author of the GeneReviews chapter on TRPV4-related disorders [6].
Hearing, and a CMT2C biomarker project
- Patient-friendly
Hearing and CMT
Dr. Ronna Hertzano, University of Maryland and National Institutes of Health · Saturday
Partial hearing loss was reported by 27% of people in the TRPV4 registry [3]. A technical version of the talk was given on the Thursday.
- Technical
Profiling neurovascular cells for biomarker discovery
Jonathan Alevy, Johns Hopkins University · Thursday
The CMTRF-funded project looking for changes in the cells that line nerve blood vessels in a lab model of CMT2C, part of the search for a blood test that could track the disease [99]. More on the biomarker work.
Treatments for other axonal forms of CMT
None of these is for CMT2C, but each tackles a form of CMT in which, as in ours, the nerve fiber itself is damaged. The Trials page explains which of them could one day matter for us.
- Technical
Development of RTX-117, an eIF2B activator targeting the integrated stress response across diverse CMT subtypes
Dr. Sridhar Narayan, ReviR Therapeutics · Friday, and a company update on Saturday
RTX-117 is in the “could work, ask the researchers” group on Trials and research.
- Technical
In vivo testing of CRISPR-Cas9 gene therapy approaches in a mouse model of CMT2E
Dr. Abigail Tadenev, Jackson Laboratory · Friday
- Technical
N-of-1 personalized therapy for CMT2S: from preclinical models to first-in-human dosing
Dr. Sandra Smieszek, Vanda Pharmaceuticals · Friday
Browse all 48 convention talks
CMTA Patient & Research Summit, 9 to 11 October 2026
The summit was in person only, at the Grand Bay Hotel in Redwood City, with NMD Pharma as presenting sponsor [322]. The recordings are on the CMTA's YouTube channel; the CMTA's own conference recordings page had not yet listed them when I checked on 31 October 2026 [323]. Besides the two panels in my picks above, these are worth watching.
Sunday: research, from discovery to delivery
- Trial readiness
Our commitment to investing in clinical trial readiness: the CMTA–INC partnership
Dr. Michael Shy, University of Iowa, and Dr. Sue Bruhn, CMTA · 28 minutes
A fireside chat on what it takes to bring a CMT treatment from the lab to a trial, how trials work, why they take time and what decides who can take part, with the presentation of the Mike Shy Lifetime Achievement Award [322].
- Already open to CMT2
Targeting shared pathways: treatments that could help many people with CMT
Daniel Brennan, NMD Pharma, and Dr. Jordan VerPlank, Uniformed Services University · 24 minutes
NMD Pharma's ignaseclant was tested in adults with CMT1 or CMT2 [45]; see how it acts.
- Pipeline
Targeting the root cause
Dr. Luke Judge, UCSF Benioff Children's Hospital, and Catherine Illingworth, Kylix Bio · 30 minutes
Genetic therapies and which subtypes they may target [322].
- Pipeline
Delivery science: the missing link in CMT treatments
Dr. John Svaren, Dr. Rachel Salzman and Dr. Brian Price · 22 minutes
- Our community
Keynote address: a patient's experience of a clinical trial
Cara Leath, CMT community member · 19 minutes
Saturday: living well with CMT
- Everyday life
Center of Excellence clinic teams
Dr. Alexander Fay and Dr. Madina Tugizova, UCSF; Dr. John Day, Stanford · 50 minutes
What a CMT Center of Excellence does, with open questions from the room. Find a center.
- Everyday life
Genetic testing for CMT
Carly Siskind, genetic counselor, Stanford · 30 minutes
- Everyday life
Pain management strategies for CMT
Dr. John Day, Stanford · 37 minutes
Half of TRPV4 registry participants reported arthritic-like pain [3]; see Pain and mental health.
- Everyday life
Staying active with CMT: PT, OT and gadgets
Natalie Anzures, physical therapist, and Jessica Mok, occupational therapist, UCSF · 38 minutes
Pairs well with the Movement guide.
- Everyday life
Patient panel: stories of living well with CMT
Dr. Julie FitzGerald and Erin Weierbach · 42 minutes
All summit recordings on the CMTA channel
What I am still adding
How this page was made. The descriptions above come from the two published programs and the video titles, not from a transcript of each talk, so they say what a session is about, not what was said in it. I am watching the sessions in my picks first and will add notes here on anything new for CMT2C, such as the timing of the STAR-0871 trial. Neither conference had a session on CMT2C breathing or voice problems; for those, our own Breathing and voice page and the CMTA's 2024 session on CMT-related breathing issues remain the best places to start.
- The FDA listening session. On 20 October 2026 the FDA heard from people with CMT2C and their families in a private session organized by the CMTA [104]. The FDA's list of listening session summaries shows ours with the note “summary coming soon” [324]. I will link it from Why ABS-0871 matters as soon as it appears.
- The CMTA's recordings page. The CMTA keeps past summit sessions on its conference recordings page, which still ends at 2024 [325]. When the 2026 sessions move there, I will update the links.
- Earlier videos. The December 2025 CMT2C/TRPV4 meeting with Actio Biosciences and the CMT Research Foundation's two talks on CMT2C by Dr. McCray are listed on the resource directory.
Also new on this site
- ABS-0871 has a new name. On 30 October 2026 Setara Biosciences (spun out of Actio Biosciences) launched as the company developing the drug, now called STAR-0871 (previously ABS-0871), with a trial in people with CMT2C planned for 2027 [318] [319]. Why it matters to us and where it stands.